Review of checkpoint immunotherapy for the management of non-small cell lung cancer

Checkpoint immunotherapy uses highly selective humanized monoclonal antibodies against checkpoint signals such as programmed cell death receptor (PD-1) and programmed cell death ligand (PD-L1). By blocking these receptors and signals, the immune system can be reactivated to fight the tumor. Immunoth...

Descripción completa

Detalles Bibliográficos
Autores principales: Raju, Shine, Joseph, Ranjit, Sehgal, Sameep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6074780/
https://www.ncbi.nlm.nih.gov/pubmed/30105218
http://dx.doi.org/10.2147/ITT.S125070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6074780/
https://www.ncbi.nlm.nih.gov/pubmed/30105218
http://dx.doi.org/10.2147/ITT.S125070

Ejemplares similares